Document is current
Any future updates will be listed below
-
Authors
Gurudas, Sarega
Marques, Inês
Girmens, Jean-François
Lechanteur, Yara
Parravano, Maria Cristina
Berger, Lieselotte
Agostini, Hansjürgen
Barrão, Sandra
Tsiroukis, Evangelos
Monés, Jordi
Sararols, Laura
Silva, Rufino https://orcid.org/0000-0001-8676-0833
Scholl, Hendrik
Lommatzsch, Albrecht
Stanzel, Boris https://orcid.org/0000-0002-4316-1539
Vujosevic, Stela https://orcid.org/0000-0001-6773-9967
Sivaprasad, Sobha https://orcid.org/0000-0001-8952-0659
,
Sivaprasad, Sobha
Scholl, Hendrik P. N.
Liermann, Yannick
Lanzetta, Paolo
Fletcher, Emily
Madhusudhan, Savita
Lytvynchuk, Lyubomyr
Bandello, Francesco
Eter, Nicole
de Cilla, Stefano
Weber, Michel
Ambresin, Aude
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
- License Information
-
More Information
Article History
Received: 18 November 2024
Revised: 22 May 2025
Accepted: 17 June 2025
First Online: 19 July 2025
Competing interests
: SS reported receiving financial support from AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, Eyepoint Pharmaceuticals, Janssen Pharmaceuticals, Nova Nordisk, Optos, Ocular Therapeutix, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics and Sanofi. SS is the Editor-in-Chief of EYE.
